Percutaneous hepatic artery infusion chemotherapy with oxaliplatin and fluoropyrimidines in treatment-resistant colorectal cancer patients with unresectable liver metastases: a retrospective cohort study

被引：0

作者：

Fong, William Pat ^{[1
]}

Li, Zi-Jing ^{[1
]}

Ren, Chao ^{[1
]}

Guan, Wen-Long ^{[1
]}

Zuo, Meng-Xuan ^{[2
]}

Zhang, Tian-Qi ^{[2
]}

Li, Bin-Kui ^{[3
]}

Zheng, Yun ^{[3
]}

Wu, Xiao-Jun ^{[4
]}

Ding, Pei-Rong ^{[4
]}

Chen, Gong ^{[4
]}

Pan, Zhi-Zhong ^{[4
]}

Yuan, Yun-Fei ^{[3
]}

Tan, Qiong ^{[1
]}

Wang, Zhi-Qiang ^{[1
]}

Li, Yu-Hong ^{[1
]}

Wang, De-Shen ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, Canc Ctr, Dept Minimally Invas & Intervent Therapy, Guangzhou, Peoples R China

[3] Sun Yat sen Univ, Canc Ctr, Dept Hepatobiliary Oncol, Guangzhou, Peoples R China

[4] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Dept Colorectal Surg,State Key Lab Oncol South Chi, Guangzhou, Peoples R China

来源：

HPB | 2025年 / 27卷 / 03期

基金：

中国国家自然科学基金;

关键词：

SYSTEMIC CHEMOTHERAPY; TRIAL; THERAPY; FLOXURIDINE; BEVACIZUMAB; LEUCOVORIN; RESECTION; SURVIVAL; TUMOR;

D O I：

10.1016/j.hpb.2024.11.008

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Subsequent lines of therapy for chemotherapy-resistant metastatic colorectal cancer (CRC) have shown limited efficacy. Herein, we retrospectively investigated the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) using oxaliplatin plus 5-FU/FUDR in patients with unresectable colorectal liver metastases (CRLM) who progressed following standard chemotherapy regimens. Methods: From March 2017 to April 2023, CRC patients with unresectable CRLM who progressed following standard chemotherapy and subsequently received HAIC oxaliplatin plus 5-FU/FUDR were evaluated. Objective response rate (ORR), disease control rate (DCR), median depth of tumor response (DpR), no evidence of disease (NED) rate, progression-free survival (PFS), overall survival (OS), and safety were assessed. Results: A total of 21 patients who progressed after a median of two (range: 1-4) lines of standard systemic chemotherapy were included. The ORR and DCR were 28.6 % and 95.2 %, respectively, with six patients reaching partial response. Additionally, the median DpR was 10.6 %, and seven patients underwent successful conversion surgery. Stratification revealed significantly better PFS in patients with liver-limited metastases compared to those with concurrent hepatic and extrahepatic metastases (P = 0.0003). Conclusion: HAIC oxaliplatin plus 5-FU/FUDR is a robust regimen for treatment-resistant CRC patients with unresectable CRLM, particularly those with liver-limited disease.

引用

页码：289 / 298

页数：10

共 50 条

[21] Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined or Not with Systemic Chemotherapy
Pilati, Pierluigi
Mammano, Enzo
Mocellin, Simone
Tessari, Emanuela
Lise, Mario
Nitti, Donato
ANTICANCER RESEARCH, 2009, 29 (10) : 4139 - 4144
[22] CETUXIMAB WITH HEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY FOR THE TREATMENT OF COLORECTAL CANCER LIVER METASTASES
Neyns, B.
Aerts, M.
Van Nieuwenhove, Y.
Fontaine, C.
De Coster, L.
Schallier, D.
Vanderauwera, J.
De Munck, F.
Vandenbroucke, F.
Everaert, H.
Meert, V.
De Mey, J.
De Ridder, M.
Delvaux, G.
De Greve, J.
ANTICANCER RESEARCH, 2008, 28 (5C) : 3185 - 3186
[23] Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases
Neyns, Bart
Aerts, Maridi
Van Nieuwenhove, Yves
Fontaine, Christel
De Coster, Lore
Schallier, Dennis
Vanderauwera, Jacques
De Munck, Floris
Vandenbroucke, Frederik
Everaert, Hendrik
Meert, Vanessa
De Mey, Johan
De Ridder, Mark
Delvaux, Georges
De Greve, Jacques
ANTICANCER RESEARCH, 2008, 28 (4C) : 2459 - 2467
[24] Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients
Coskun, U.
Buyukberber, S.
Yaman, E.
Uner, A.
Er, O.
Ozkan, M.
Dikilitas, M.
Oguz, M.
Yildiz, R.
Yamac, D.
Ozturk, B.
Kaya, A. O.
Benekli, M.
NEOPLASMA, 2008, 55 (01) : 65 - 70
[25] Adjuvant hepatic artery infusion pump chemotherapy for resected colorectal cancer liver metastases
Standring, Oliver
Gholami, Sepideh
SURGERY, 2023, 174 (03) : 747 - 749
[26] Hepatic Artery Infusion in the Treatment of Colorectal Cancer Metastases
Choo, Su-Pin
Venook, Alan P.
CURRENT COLORECTAL CANCER REPORTS, 2008, 4 (02) : 106 - 113
[27] Results of Hepatic Arterial Infusion Chemotherapy in Patients with Unresectable Liver Metastases
Goi, Takanori
Sawai, Katsuji
Koneri, Kenji
Katayama, Kanji
Yamaguchi, Akio
VISZERALMEDIZIN, 2011, 27 (05): : 397 - 401
[28] Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma
Kemeny, Nancy E.
Melendez, Fidel D. Huitzil
Capanu, Marinela
Paty, Philip B.
Fong, Yuman
Schwartz, Lawrence H.
Jarnagin, William R.
Patel, Dina
D'Angelica, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3465 - 3471
[29] Hepatic Artery Infusion Chemotherapy Compared to Y90 for Treatment of Unresectable Colorectal Liver Metastases: A Multi-Institutional Comparative Study
Saadat, Lily V.
Chou, Joanne
Gonen, Mithat
Lee, Rachel M.
Maithel, Shishir K.
Li, Amy Y.
Poultsides, George
Aiken, Taylor J.
Schwartz, Patrick B.
Abbott, Daniel E.
Robbins, Keenan J.
Fields, Ryan C.
Paranjpe, Ashwini
Datta, Jashodeep
Jarnagin, William R.
Cercek, Andrea
Kemeny, Nancy E.
Sze, Daniel
Sofocleous, Constantinos
D'Angelica, Michael I.
ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S29 - S30
[30] Unresectable Liver Metastases from Colorectal Cancer and Hepatic Arterial Infusion Chemotherapy: How, When and to Whom?
Viudez, Antonio
Rodriguez, Javier
Gil-Bazo, Ignacio
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2009, 32 (03) : 603 - 604

← 1 2 3 4 5 →